| calcipotriol/betamethasone dipropionate / Generic mfg. |
NCT00216892 / 2004-004577-28: Efficacy and Safety of Calcipotriol Cream and (Calcipotriol + Betamethasone Dipropionate) Ointment in Psoriasis Vulgaris |
|
|
| Completed | 4 | 1032 | Canada, Europe | Calcipotriol, (calcipotriol + betamethasone) | LEO Pharma | Psoriasis Vulgaris | | 12/05 | | |
|
NCT00248456: Efficacy and Safety of Calcipotriol Plus Betamethasone Dipropionate Ointment in Patients With Psoriasis Vulgaris |
|
|
| Completed | 4 | 320 | RoW | Calcipotriol plus betamethasone dipropionate ointment | LEO Pharma | Psoriasis Vulgaris | | 02/06 | | |
NCT00437255: Efficacy, Safety, Preference and Response Duration of Clobex® Spray and Taclonex® Ointment in Psoriasis |
|
|
| Completed | 4 | 122 | US | Clobetasol Propionate, 0.05%, Clobex® Spray, Calcipotriene and betamethasone dipropionate ointment, Taclonex® Ointment | Galderma R&D | Plaque Psoriasis | 06/07 | 06/07 | | |
NCT00608777: Effect of Topical Calcipotriene/Betamethasone (Taclonex) in Managing Localized Breakthrough in Moderate to Severe Plaque Psoriasis in Patients Receiving Efalizumab (Raptiva) |
|
|
| Terminated | 4 | 6 | US | Calcipotriene/betamethasone, Taclonex | Derm Research, PLLC, Genentech, Inc. | Plaque Psoriasis | 02/09 | 02/09 | | |
NCT00437619: A Study of Sequential Treatment With Daivobet (Betamethasone Dipropionate Plus Calcipotriol) and Daivonex (Calcipotriol) in Patients With Psoriasis. |
|
|
| Completed | 4 | 200 | RoW | calcipotriol hydrate [Daivonex] | Hoffmann-La Roche | Psoriasis | 08/09 | 08/09 | | |
NCT00924950: Taclonex Ointment With Hydrogel Patch Occlusion for the Treatment of Psoriasis |
|
|
| Terminated | 4 | 35 | US | Taclonex Ointment and Hydrogel Patch, Taclonex Ointment | University of California, San Francisco | Plaque Psoriasis, Psoriasis Vulgaris | 12/09 | 12/09 | | |
PSTaclonex, NCT01707043: Patient Preference of Taclonex Ointment to Taclonex Scalp Suspension in Adult Subjects With Psoriasis Vulgaris |
|
|
| Completed | 4 | 20 | US | Taclonex, Taclonex® Ointment, (calcipotriene 0.005% betamethasone dipropionate 0.064%), Taclonex Scalp®, (calcipotriene 0.005% and betamethasone dipropionate 0.064%), Topical Suspension | Wake Forest University, LEO Pharma | Plaque Psoriasis | 09/13 | 12/13 | | |
ChiCTR-TRC-12003543: A Multi-center, randomized, double-blinded, double-dummy, parallel-controlled clinical trial to determine the efficacy and safety of calcipotriol ointment, betamethasone dipropionate ointment and calcipotriol/betamethasone ointment in patients with mild psoriasis vulgaris |
|
|
| Completed | 4 | 720 | | Topical use Calcipotriol Ointment，twice per day ;Topical use the placebo in the morning and betamethasone dipropionate cream in the evening ;Topical use the placebo in the morning and calcipotriol/betamethasone in the evening | Institute of dermatology, Chinese Academyof Medical Sciences; Institute of Dermatology, Chinese Academyof Medical Sciences, the Research Special Fund for Public Welfare Industry of Health No. 201002016 | Mild Psoriasis Vulgaris | | | | |
| Completed | 4 | 1852 | Europe | TTOP, non-TTOP | Kristian Reich, MD, LEO Pharma | Mild to Moderate Psoriasis | 06/14 | 06/14 | | |
TRIANGLE, NCT02004574: Study for Treatment With Calcipotriol/Betamethasone Dipropionate Gel in Korean Patients With Psoriasis Vulgaris |
|
|
| Completed | 4 | 201 | RoW | Calcipotriol/betamethasone dipropionate gel, Xamiol gel | Jooheung Lee | Psoriasis Vulgaris | 06/14 | 06/14 | | |
NCT01761019: A Study to Determine the Efficacy of Taclonex Topical Suspension as a Supplement to Non-biologic Systemic Therapy |
|
|
| Completed | 4 | 8 | US | Taclonex Topical Suspension | University of Pittsburgh, LEO Pharma | Psoriasis | 09/14 | 09/14 | | |
2009-016969-28: Multicentre, prospective, assessor-blind, in parallel groups randomised and controlled trial of the efficacy and safety of betamethasone valerate 2.25mg medicated plaster (Betesil®, IBSA-Institut Biochimique S.A.) versus 50μg-0,5mg/g calcipotriol-betamethasone (dipropionate) ointment (Daivobet®/Dovobet®, LEO Pharmaceutical Products), in the treatment of chronic plaque psoriasis. |
|
|
| | 4 | 130 | Europe | Betesil® 2.250 medicated plaster, DAIVOBET 50 microgrammes/0,5 mg/g, pommade, Betesil® 2.250 medicated plaster, DAIVOBET 50 microgrammes/0,5 mg/g, pommade | IBSA, Institut Biochimique SA, IBSA INSTITUT BIOCHIMIQUE SA | chronic plaque psoriasis (psoriasis vulgaris) | | 01/11 | | |
NCT02733874: A Trial That Compound Clobetasol Propionate Ointment Treats Patients With Mild to Moderate Psoriasis Vulgaris. |
|
|
| Completed | 4 | 240 | RoW | Compound Clobetasol Propionate Ointment, Calcipotriol Betamethasone Ointment | First Hospital of China Medical University | Psoriasis | 04/16 | | | |
ChiCTR-IPR-16008126: A multi-center, randomized, single blind, positive controlled trials that assess the effect, safety and cost in patients with mild to moderate psoriasis vulgaris and compare Fufangbingsuanlvbeitasuo (Jinniuer) ointment to Gaibosanchunbeitamisong (Defubao) ointment |
|
|
| Completed | 4 | 240 | | Compound Clobetasol Propionate Ointment group, 2 times a day, continuous treatment for 4 weeks, the local external use for psoriasis ;Calcipotriol Betamethasone Ointment group, 1 times a day, for 4 consecutive weeks. The local external for psoriasis. | The First Hospital of China Medical University; The original Jiangsu Pharmaceutical Co. Ltd., Provided by Sponsor | Mild to moderate psoriasis | | | | |
NCT02533973: Long-term Treatment of Scalp Psoriasis With Xamiol® Gel in a Large Adult Chinese Population |
|
|
| Completed | 4 | 951 | RoW | Xamiol® gel, Daivonex® scalp solution | LEO Pharma, Tigermed Consulting Co., Ltd | Psoriasis Vulgaris | 03/18 | 03/18 | | |
ChiCTR2300072465: Prospective, open-label, interventional, multi-centre, hybrid-virtual, exploratory treatment outcome study on the long-term efficacy of calcipotriol betamethasone ointment in the treatment of plaque psoriasis |
|
|
| Not yet recruiting | 4 | 150 | | Initial treatment: Patients will apply Calcipotriol and Betamethasone Ointment once daily until they achieve PGA 0/1 then continue to apply once a day for another 4 weeks. Patients with stable disease will enter the maintenance treatment phase. Maintenance treatment: After induction of remission, Calcipotriol and Betamethasone Ointment should be applied once daily to previously affected skin areas for two consecutive days per week eg, weekends and will be continued for up to 26 weeks. *Restart initial treatment if patient experience disease relapse during maintenance therapy. ;Initial treatment: Patients will apply Calcipotriol and Betamethasone Ointment once daily until they achieve PGA 0/1 then continue to apply once a day for another 4 weeks. Patients with stable disease will enter the maintenance treatment phase. Maintenance treatment: After induction of remission, Calcipotriol Ointment should be applied twice daily to previously affected skin areas for two consecutive days per week eg, weekends and will be continued for up to 26 weeks. *Restart initial treatment if patient experience disease relapse during maintenance therapy. | Xijing Hospital of Air Force Military Medical University; Xijing Hospital of Air Force Military Medical University, China Primary Health Care Foundation-LEO Dermatology Research Foundation | Psoriasis | | | | |
